I think to make any sense out of this article, you would have to have more information. Basically, 148 started treatment with Arikace. 146 patients were treated with TOBI. At the end of the study there were 129 Arikace and 137 TOBI patients in the per protocol group, or 28 fewer patients than at the beginning. [19 Arikace and 9 TOBI patients missing.] I guess Feuerstein is saying Tobi is better because fewer patients dropped out. I would need more info such as why the 28 patients discontinued the treatment. Shorts are desperate after last weeks run up.